GlaxoSmithKline Inc. (GSK) stock rises in the pre-market trading. Let’s find out why?

GlaxoSmithKline Inc. (GSK) stock surged by 0.25% at the last trading close whereas the GSK stock price continued to rise by 5.4% in the pre-market trading session. GSK is a leading healthcare organization based on research, with a mission to help people do more, feel better, and live longer. GSK operates three multinational companies that produce, manufacture, and market breakthrough prescription drugs, vaccines, and consumer healthcare products. Every day, GSK contributes to the betterment of the wellbeing of millions of people all over the world. GSK aspires to be one of the most creative, high-performing and trusted healthcare organizations in the country.

Important Collaborations with other companies

  • Zentalis Pharmaceuticals and GlaxoSmithKline are working together to test the combination of ZN-c3 and Zejula (niraparib) in patients with advanced epithelial ovarian cancer. Zentalis is responsible for conducting the research under the terms of the non-exclusive agreement, with GSK providing niraparib. ZN-c3 is fully owned by Zentalis.
  • COVID-19 vaccine candidates are being developed by GlaxoSmithKline in collaboration with a number of other organizations. However, the large pharmaceutical company is still assisting in the production of Novavax’s COVID-19 vaccine, despite the fact that it was not involved in its development.


Anvisa, the Brazilian health regulator, authorized the start of clinical trials for a new COVID vaccine developed by Medicago R&D and GlaxoSmithKline PLC in the country on Thursday. Medicago and GSK have been given permission to perform phase 3 trials in the region, according to Anvisa. In the United States, Canada, Europe, and Latin America, the firms expect to research the latest vaccines on about 30,000 individuals. Around 3,500 volunteers from Brazil are expected to participate in the trials. In Brazil, this will be the fifth COVID vaccine clinical trial.